Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548228 | 1.00 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL18956334 | 0.89 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL18247419 | 0.89 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL28546354 | 0.89 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL29187885 | 0.89 | CTSK (0.42) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL29286133 | 0.87 | CTSK (0.39) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL20722717 | 0.87 | CTSK (0.39) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL5132958 | 0.87 | CTSK (0.39) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL4436916 | 0.84 | CTSK (0.38) | CTSKCA1CA2HSD11B1CYP2C9 | |
| SCHEMBL3131378 | 0.83 | CTSK (0.44) | CTSKCA1CA2HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9676762-B2 | Pyrimidine compounds containing seven-membered fused ring systems | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160362404-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-8846689-B2 | Substituted pyrimidines for the treatment of diseases such as cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| WO-2010058032-A2 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371205-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | CTSK 3604/4885CA1 4735/4885CA2 4417/4885 |
| US-20160362404-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | CTSK 3862/4885CA1 4538/4885CA2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.